SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
ImmunityFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

Thymogen

Also known as oglufanide, thymogen, timogen, im-862, ew

Thymogen is the synthetic dipeptide L-glutamyl-L-tryptophan (Glu-Trp, EW), also known as oglufanide and IM-862. It was developed in the Soviet Union as the smallest active fragment of Thymalin and is approved in Russia and several CIS countries as an immune modulator. Oglufanide disodium, the same molecule, was investigated in the West by Implicit Bioscience in Phase II trials for hepatocellular carcinoma based on antiangiogenic activity. Russian use targets secondary immunodeficiency, post-surgical recovery, and viral infections. It is not approved by FDA, EMA, or UK MHRA.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Thymogen / Oglufanide / Bestim is the synthetic dipeptide L-glutamyl-L-tryptophan (Glu-Trp / EW), isolated as the smallest active fragment of Thymalin. As an immune bioregulator it is reported to increase CD4+ T-helper cells, normalize T-helper / T-suppressor ratios, enhance macrophage and neutrophil phagocytic activity, and restore IL-2 production.

Thymogen / Oglufanide / Bestim is the synthetic dipeptide L-glutamyl-L-tryptophan (Glu-Trp / EW), isolated as the smallest active fragment of Thymalin. As an immune bioregulator it is reported to increase CD4+ T-helper cells, normalize T-helper / T-suppressor ratios, enhance macrophage and neutrophil phagocytic activity, and restore IL-2 production. A distinct Western development thread (oglufanide disodium, Implicit Bioscience) investigated antiangiogenic activity for hepatocellular carcinoma in Phase 2 trials (PubMed 11707921). The defined receptor target has not been established; activity is attributed to brief but high-affinity engagement of immune effector cells and possibly gene-regulatory effects typical of short Khavinson-style bioregulators.

Pharmacokinetic properties

Half-life

very short - minutes in plasma; activity attributed to brief but high-affinity receptor engagement

Routes

intramuscular · subcutaneous · intranasal · sublingual

Bioavailability

Intranasal route is the most common Russian clinical delivery (0.01% spray). Sublingual and parenteral forms also marketed. Oral bioavailability assumed minimal because of GI peptidases.

Amino-acid sequence

Glu-Trp (EW)

Use & research dosing

Immune ModulationAnti-inflammatoryRecovery

Russian approved-label use specifies 100 mcg intramuscularly daily for 3-10 days, or one spray (25-50 mcg) per nostril 2-3 times daily for the 0.01% intranasal formulation. Research-channel self-experimentation commonly reports 100 mcg subcutaneously or intranasally daily for 5-10 day cycles, repeated as needed. Western Phase 2 oncology trials with oglufanide disodium used IV infusion regimens. No FDA-approved dose exists. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Smallest practical thymic-peptide bioregulator. Dual identity is important: in Russia (Thymogen) it is approved as an immune modulator; in Western Phase II oncology trials (oglufanide / IM-862, Implicit Bioscience) it has been investigated as an antiangiogenic in hepatocellular carcinoma. Russian approval does not constitute FDA, EMA, or UK MHRA approval. Independent Western replication of immune-modulator efficacy is limited.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Evidence base is almost entirely Russian / Eastern European
  • Not approved by FDA, EMA, or UK MHRA
  • Phase 2 Western development (oglufanide / IM-862 in HCC) did not advance to registration
  • Caution in autoimmune disease given immune modulation
  • Pregnancy and lactation - insufficient data
  • Vendor sterility and identity assurance highly variable
  • Dual identity (immune modulator vs antiangiogenic anticancer) means mechanism context differs by indication
  • Long-term safety data outside short Russian dosing cycles are limited

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/11707921/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/12420072/

Facts verified

2026-05-25

Confidence

low

What this means

  • evidence base primarily Russian; Western Phase 2 (HCC) did not advance
  • dual identity: immune modulator (Russia) vs antiangiogenic (Western oncology)
  • incorrect clinical_status in source - corrected to Approved (other jurisdiction)

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.